Literature DB >> 12439663

Treatment of gustatory hyperlacrimation (crocodile tears) with injection of botulinum toxin into the lacrimal gland.

F J Montoya1, C E Riddell, R Caesar, S Hague.   

Abstract

PURPOSE: To establish the efficacy and safety of botulinum toxin in the treatment of Crocodile Tear Syndrome and record any possible complications.
METHODS: Four patients with unilateral aberrant VII cranial nerve regeneration following an episode of facial paralysis consented to be included in this study after a comprehensive explanation of the procedure and possible complications was given. On average, an injection of 20 units of botulinum toxin type A (Dysport) was given to the affected lacrimal gland. The effect was assessed with a Schirmer's test during taste stimulation. Careful recording of the duration of the effect and the presence of any local or systemic complications was made.
RESULTS: All patients reported a partial or complete disappearance of the reflex hyperlacrimation following treatment. Schirmer's tests during taste stimulation documented a significant decrease in tear secretion. The onset of effect of the botulinum toxin was typically 24-48 h after the initial injection and lasted 4-5 months. One patient had a mild increase in his preexisting upper lid ptosis, but no other local or systemic side effects were experienced.
CONCLUSIONS: The injection of botulinum toxin type A into the affected lacrimal glands of patients with gusto-lacrimal reflex is a simple, effective and safe treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12439663     DOI: 10.1038/sj.eye.6700230

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  16 in total

Review 1.  Long term efficacy and safety of botulinum toxin A injection for crocodile tears syndrome.

Authors:  D E Barañano; N R Miller
Journal:  Br J Ophthalmol       Date:  2004-04       Impact factor: 4.638

2.  [Botulinum toxin for the treatment of secretory disorders of the head and neck area].

Authors:  A Steffen
Journal:  HNO       Date:  2012-06       Impact factor: 1.284

3.  Treg-recruiting microspheres prevent inflammation in a murine model of dry eye disease.

Authors:  Michelle L Ratay; Andrew J Glowacki; Stephen C Balmert; Abhinav P Acharya; Julia Polat; Lawrence P Andrews; Morgan V Fedorchak; Joel S Schuman; Dario A A Vignali; Steven R Little
Journal:  J Control Release       Date:  2017-05-10       Impact factor: 9.776

4.  Botulinum toxin therapy: its use for neurological disorders of the autonomic nervous system.

Authors:  Dirk Dressler
Journal:  J Neurol       Date:  2012-08-10       Impact factor: 4.849

5.  Dry eye syndrome due to botulinum toxin type-A injection: guideline for prevention.

Authors:  Omar K Ozgur; Daniel Murariu; Alan A Parsa; Fereydoun Don Parsa
Journal:  Hawaii J Med Public Health       Date:  2012-05

6.  Comparison of botulinum toxin-A injection in lacrimal gland and conjunctivodacryocystorhinostomy for treatment of epiphora due to proximal lacrimal system obstruction.

Authors:  P Kaynak; G O Karabulut; C Ozturker; K Fazil; Y O Arat; I Perente; S Akar; O F Yilmaz; A Demirok
Journal:  Eye (Lond)       Date:  2016-05-20       Impact factor: 3.775

Review 7.  Lacrimal gland botulinum toxin injection for epiphora management.

Authors:  Johnathan Jeffers; Katherine Lucarelli; Sruti Akella; Pete Setabutr; Ted H Wojno; Vinay Aakalu
Journal:  Orbit       Date:  2021-08-15

8.  Noncosmetic periocular therapeutic applications of botulinum toxin.

Authors:  Pelin Kaynak-Hekimhan
Journal:  Middle East Afr J Ophthalmol       Date:  2010-04

9.  Intraglandular injection of botulinum toxin a reduces tear production in rabbits.

Authors:  Anna M Demetriades; Ilya M Leyngold; Sam D'Anna; Allen O Eghrari; Dave G Emmert; Michael P Grant; Shannath L Merbs
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2013 Jan-Feb       Impact factor: 1.746

Review 10.  [Botulinum toxin treatment for crocodile tears, spastic entropion and for dysthyroid upper eyelid retraction].

Authors:  B Wabbels; M Förl
Journal:  Ophthalmologe       Date:  2007-09       Impact factor: 1.174

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.